280 related articles for article (PubMed ID: 30226534)
1. Sulforaphane regulates apoptosis- and proliferation‑related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer.
Kan SF; Wang J; Sun GX
Int J Mol Med; 2018 Nov; 42(5):2447-2458. PubMed ID: 30226534
[TBL] [Abstract][Full Text] [Related]
2. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
3. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
4. Songorine suppresses cell growth and metastasis in epithelial ovarian cancer via the Bcl‑2/Bax and GSK3β/β‑catenin signaling pathways.
Zhang H; Dong R; Zhang P; Wang Y
Oncol Rep; 2019 May; 41(5):3069-3079. PubMed ID: 30896826
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
Jakubikova J; Cervi D; Ooi M; Kim K; Nahar S; Klippel S; Cholujova D; Leiba M; Daley JF; Delmore J; Negri J; Blotta S; McMillin DW; Hideshima T; Richardson PG; Sedlak J; Anderson KC; Mitsiades CS
Haematologica; 2011 Aug; 96(8):1170-9. PubMed ID: 21712538
[TBL] [Abstract][Full Text] [Related]
6. Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression.
Gong TT; Guo Q; Li X; Zhang TN; Liu FH; He XH; Lin B; Wu QJ
Biomed Pharmacother; 2021 Oct; 142():111533. PubMed ID: 34148735
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells.
Chaudhuri D; Orsulic S; Ashok BT
Mol Cancer Ther; 2007 Jan; 6(1):334-45. PubMed ID: 17237292
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
[TBL] [Abstract][Full Text] [Related]
9. Alpinetin inhibits proliferation and migration of ovarian cancer cells via suppression of STAT3 signaling.
Zhao X; Guo X; Shen J; Hua D
Mol Med Rep; 2018 Oct; 18(4):4030-4036. PubMed ID: 30132572
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
11. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells.
Leng Y; Zhao C; Yan G; Xu S; Yang Y; Gong T; Li X; Li C
J Ovarian Res; 2021 Nov; 14(1):162. PubMed ID: 34789301
[TBL] [Abstract][Full Text] [Related]
13. Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells.
Deng Y; Zhang J; Wang Z; Yan Z; Qiao M; Ye J; Wei Q; Wang J; Wang X; Zhao L; Lu S; Tang S; Mohammed MK; Liu H; Fan J; Zhang F; Zou Y; Liao J; Qi H; Haydon RC; Luu HH; He TC; Tang L
Sci Rep; 2015 Dec; 5():17523. PubMed ID: 26639992
[TBL] [Abstract][Full Text] [Related]
14. Synthetic isothiocyanate indole-3-ethyl isothiocyanate (homoITC) enhances sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to cisplatin.
Stehlik P; Paulikova H; Hunakova L
Neoplasma; 2010; 57(5):473-81. PubMed ID: 20568902
[TBL] [Abstract][Full Text] [Related]
15. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract][Full Text] [Related]
16. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion.
Wang H; Luo Y; Qiao T; Wu Z; Huang Z
J Ovarian Res; 2018 Nov; 11(1):93. PubMed ID: 30454003
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
Wu W; Yu LH; Ma B; Xu MJ
PLoS One; 2014; 9(3):e89841. PubMed ID: 24598933
[TBL] [Abstract][Full Text] [Related]
18. Modulation of Myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors.
Tian M; Tian D; Qiao X; Li J; Zhang L
J Cell Physiol; 2019 Nov; 234(11):21126-21134. PubMed ID: 31037726
[TBL] [Abstract][Full Text] [Related]
19. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
